Haloperidol induces neuroprotection and enhances neuromuscular function in both murine and human models of SMA

Haloperidol induces neuroprotection and enhances neuromuscular function in both murine and human models of SMA

Experimental & Molecular Medicine, 13 April 2026

Haloperidol induces neuroprotection and enhances neuromuscular function in both murine and human models of spinal muscular atrophy

 

Menduti G, Perez-Gomez R, Berenger-Currias N, Ruatti C, Espinosa-Espinosa J, Januel C, Konieczny P, Artero R, Martinat C, Boido M.

 

NICO Research Group: Brain development and disease

 

Spinal muscular atrophy (SMA) is a severe neuromuscular disorder caused by Survival Motor Neuron 1 (SMN1) gene mutations, leading to reduced SMN protein levels and progressive motor neuron (MN) degeneration. Although current therapies aim to restore SMN expression, limitations highlight the need for alternative strategies.

We investigated haloperidol (HALO), a classical antipsychotic, as a potential therapeutic based on its ability to enhance SMN2 splicing and SMN expression. Using the delta 7 SMA mouse model, we assessed effects of HALO on survival, motor function, neuroprotection, and neuroinflammation, by histological, molecular, and RNA-sequencing analyses of spinal cord and muscle samples.

Additionally, we examined patient induced pluripotent stem cell-derived MNs and myotube co-cultures for validation in human cells. HALO increased lifespan and motor performance in mice with SMA, upregulated SMN protein in spinal cord and muscles, reduced MN loss, and attenuated neuroinflammation. Moreover, HALO enhanced neuromuscular junction integrity and muscle trophism, suggesting peripheral benefits. RNA-sequencing analysis revealed extensive splicing changes, including SMN target transcripts, supporting enhanced activity. In human models, HALO improved MN survival and SMN expression, supporting dual SMN-dependent and neuroprotective mechanisms. Given its central nervous system penetrance and clinical approval, HALO emerges as a promising SMA therapy candidate, warranting further dose optimization and validation for translational potential.

OPEN ACCESS go to full article

 

The schematic summarizes the main effects induced in vivo and in vitro by haloperidol administration: improvement in motor performance and survival in animals, delay of neuronal degeneration, reduction of neuroinflammation, improvement of muscle trophism and innervation, and modulation of RNA splicing and regulation of gene expression.

 


prof. Marina Boido and dr. Giovanna Menduti

An international project funded by SMA Europe

These results were obtained as part of an international project funded by SMA Europe, coordinated by Professor Marina Boido, in collaboration with Professor Artero (University of Valencia) and Dr. Martinat (I-Stem, France).

 

Subscribe to our newsletter
Stay updated on news and projects

Subscribe to our newsletter
Stay updated on news and projects